Sutro Biopharma stockholders elect Lobacki, Petree; ratify EY; approve say-on-pay & ESPP amendment

SUTRO BIOPHARMA, INC.

Joseph M. Lobacki re-elected with 49.6M shares For (1.4M Withheld); Daniel H. Petree re-elected with 33.4M For (17.6M Withheld).
Ernst & Young ratified as independent auditor for FY 2024: 64.6M For, 118.9K Against, 161.9K Abstain.
Non-binding advisory approval of named executive officer compensation: 50.2M For, 171.2K Against, 587.3K Abstain.
Amendment to 2018 Employee Stock Purchase Plan approved: 50.2M For, 618.7K Against, 129.4K Abstain (increase share limit + clarifying revisions).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.